Australia markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.60-0.33 (-4.16%)
At close: 04:00PM EST
7.60 0.00 (0.00%)
After hours: 06:03PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 865.95M
Enterprise value 310.03M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.70
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.43

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-84.35%
S&P500 52-week change 322.93%
52-week high 353.61
52-week low 36.68
50-day moving average 38.47
200-day moving average 311.40

Share statistics

Avg vol (3-month) 3525.2k
Avg vol (10-day) 3628k
Shares outstanding 5115M
Implied shares outstanding 6N/A
Float 841.34M
% held by insiders 165.40%
% held by institutions 129.88%
Shares short (14 Nov 2021) 43.31M
Short ratio (14 Nov 2021) 47.33
Short % of float (14 Nov 2021) 45.65%
Short % of shares outstanding (14 Nov 2021) 42.88%
Shares short (prior month 14 Oct 2021) 43.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Mar 2021
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-15.69%
Return on equity (ttm)-26.28%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -128M
Net income avi to common (ttm)-128.11M
Diluted EPS (ttm)-1.27
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)558.95M
Total cash per share (mrq)4.86
Total debt (mrq)3.03M
Total debt/equity (mrq)0.57
Current ratio (mrq)19.86
Book value per share (mrq)4.66

Cash flow statement

Operating cash flow (ttm)-86.57M
Levered free cash flow (ttm)-40.28M